CCNG1 and hepatocellular carcinoma: Data showed that miR-122-transfected ADSC-Exos combined with sorafenib could efficiently increase the chemosensitivity of HCC cells by altering target gene expression, such as cyclin G1 (CCNG1), a disintegrin and metalloprotease 10 (ADAM10), and insulin-like growth factor receptor 1 (IGF1R), and then enhance cell apoptosis and cell cycle arrest in the G0/G1 population in vitro and in vivo [96].